SCHEMBL3966031

SCHEMBL3966031

FC(F)(F)c1ccc([C@H]2NCCc3nccnc32)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.49
KDM1A O60341 4/20 0.47
TRPM8 Q7Z2W7 5/20 0.42
HTR2C P28335 3/20 0.41
LMNA P02545 1/20 0.38
RAB9A P51151 1/20 0.36
NISCH Q9Y2I1 1/20 0.36
ALDH1A1 P00352 1/20 0.35
POLB P06746 1/20 0.35
RECQL P46063 1/20 0.34
MAOB P27338 1/20 0.33
CCNB2 O95067 1/20 0.33
CDK1 P06493 1/20 0.33
CCNB1 P14635 1/20 0.33
GSK3A P49840 1/20 0.33
GSK3B P49841 1/20 0.33
CCNB3 Q8WWL7 1/20 0.33
KIF11 P52732 1/20 0.33
HTR2A P28223 1/20 0.32
HTR2B P41595 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3957475 1.00 L3MBTL1 (0.49) L3MBTL1KDM1ATRPM8HTR2CLMNA
SCHEMBL3956419 0.80 KDM1A (0.51) L3MBTL1KDM1ATRPM8HTR2CRAB9A
SCHEMBL4064540 0.80 KDM1A (0.51) L3MBTL1KDM1ATRPM8HTR2CRAB9A
SCHEMBL3956423 0.80 KDM1A (0.51) L3MBTL1KDM1ATRPM8HTR2CRAB9A
SCHEMBL3962688 0.80 L3MBTL1 (0.53) L3MBTL1KDM1ATRPM8HTR2CRECQL
SCHEMBL4063542 0.73 KDM1A (0.50) L3MBTL1KDM1ATRPM8HTR2CLMNA
SCHEMBL3964346 0.69 KDM1A (0.58) L3MBTL1KDM1ATRPM8HTR2CRECQL
SCHEMBL4076023 0.69 KDM1A (0.58) L3MBTL1KDM1ATRPM8HTR2CRECQL
SCHEMBL6996372 0.67 L3MBTL1 (0.48) L3MBTL1KDM1AHTR2CNISCHALDH1A1
SCHEMBL4156479 0.67 HTR2A (0.37) L3MBTL1KDM1ATRPM8HTR2CHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009038812-A1 CONDENSED PIPERIDINE DERIVATIVES USEFUL AS VANILLOID RECEPTOR LIGANDS AMGEN INC. (US) 2009-03-26 WO disclosed
WO-2009038812-A1 CONDENSED PIPERIDINE DERIVATIVES USEFUL AS VANILLOID RECEPTOR LIGANDS AMGEN INC. (US) 2009-03-26 WO disclosed
US-20090082358-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2009-03-26 US disclosed
US-20090082358-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2009-03-26 US disclosed
US-20090082358-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2009-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082358-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV3, TRPV2 L3MBTL1 4623/4885KDM1A 3375/4885TRPM8 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.